The Therapeutic Goods Administration is experiencing system issues linked to global Microsoft outages. Some services may be disrupted and we may take longer to respond to email and phone contact during this time.
AusPAR: Canakinumab
Australian Public Assessment Report
Device/Product Name
Ilaris
Active ingredients
Canakinumab
AusPAR Date
Published
Submission Number
PM-2013-01501-1-3
Submission Type
Extension of indications
Decision
Approved